Advertisement

Uric Acid Nephrolithiasis: Uric Acid or Urine pH?

  • Khashayar SakhaeeEmail author
Chapter
  • 632 Downloads

Abstract

The prevalence of uric acid nephrolithiasis in the general US population is approximately 8 %. However, the prevalence of uric acid stones among diabetic and obese populations has been reported to be significantly high, approaching 3.5-fold greater than the general population. Although three main etiologic factors, including low urine volume, hyperuricosuria, and unduly urine acidity, have been implicated in the pathogenesis of uric acid nephrolithiasis, abnormal urine pH has been shown to play a key pathogenic role in uric acid precipitation and uric acid stone formation. Uric acid is a weak organic acid with an ionization constant (pKa = 5.5); hence, at a urinary pH ≤ 5.5 the urinary environment becomes supersaturated with highly insoluble undissociated uric acid, which greatly imposes the risk of uric acid development and precipitation. Under normal circumstances, uric acid solubility is limited to 96 mg/L; thus, humans with urinary uric acid excretion of approximately 600–800 mg/day must be at risk for uric acid precipitation. However, urinary pH plays a dominate role in keeping uric acid in the solution. Careful studies have demonstrated that at urinary pH between 6.2 and 6.4, the urinary environment becomes undersaturated with respect to undissociated uric acid content. Such an environment has been shown to be associated with a significantly reduced risk of uric acid stone formation. Given this predominate role of urinary pH, urinary uric acid must exceed 1,100 mg/day in order to promote uric acid precipitation. This condition rarely occurs in the majority of patients with idiopathic nephrolithiasis in whom urinary acid excretion was reported to be normal. Uric acid-lowering drugs must only be tried in some patients with primary gout, with genetic abnormalities in uric acid pathways including inborn errors in metabolism, uric acid metabolism, and those with accelerated tissue turnover.

Keywords

Nephrolithiasis Uric acid Metabolic syndrome Urine pH 

Notes

Acknowledgments

The author would like to acknowledge Ashlei L. Johnson for her primary role in the preparation and editorial review of this manuscript.

The author was supported by the National Institutes of Health Grant R01-DK81423.

References

  1. 1.
    Mandel NS, Mandel GS. Urinary tract stone disease in the United States veteran population. 2. Geographical analysis of variations in composition. J Urol. 1989;142:1516–21.PubMedGoogle Scholar
  2. 2.
    Pak CY, Sakhaee K, Moe O, Preminger GM, Poindexter JR, Peterson RD, et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003;61:523–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Lieske JC, de la Vega LS, Gettman MT, Slezak JM, Bergstralh EJ, Melton LJ 3rd, et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. AM J Kidney Dis. 2006;48:897–904.PubMedCrossRefGoogle Scholar
  4. 4.
    Ekeruo WO, Tan YH, Young MD, Dahm P, Maloney ME, Mathias BJ, et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol. 2004;172:159–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res. 2006;34:193–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17:2026–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Portis AJ, Hermans K, Culhane-Pera KA, Curhan GC. Stone disease in the Hmong of Minnesota: initial description of a high-risk population. J Endourol. 2004;18:853–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Portis AJ, Laliberte M, Tatman P, Moua M, Culhane-Pera K, Maalouf NM, et al. High prevalence of gouty arthritis among the Hmong population in Minnesota. Arthritis Care Res (Hoboken). 2010;62:1386–91.CrossRefGoogle Scholar
  9. 9.
    Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol. 2006;17:1422–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Prasongwatana V, Sriboonlue P, Suntarapa S. Urinary stone composition in North-East Thailand. Br J Urol. 1983;55:353–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Herbstein FH, Kleeberg J, Shalitin Y, Wartski E, Wielinski S. Chemical and x-ray diffraction analysis of urinary stones in Israel. Isr J Med Sci. 1974;10:1493–9.PubMedGoogle Scholar
  12. 12.
    Sakhaee K. Uric acid metabolism and uric acid stones. In: Rao NP, Preminger GM, Kavanagh JP, editors. Urinary tract stone disease. Manchester: Springer; 2011.p. 185–93.Google Scholar
  13. 13.
    Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009;75:585–95.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. Curr Opin Nephrol Hypertens. 2003;12:511–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Sakhaee K, Adams-Huet B, Moe OW, Pak CY. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62:971–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Asplin JR. Uric acid stones. Sem Nep. 1996;16:412–24.Google Scholar
  17. 17.
    Coe FL, Strauss AL, Tembe V, Le Dun S. Uric acid saturation in calcium nephrolithiasis. Kidney Int. 1980;17:662–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Finlayson B, Smith A. Stability of first dissociable proton of uric acid. J Chem Eng Data. 1974;19:94–7.CrossRefGoogle Scholar
  19. 19.
    Sakhaee K, Nicar M, Hill K, Pak CY. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int. 1983;24:348–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Gutman AB, Yu TF. Uric acid nephrolithiasis. Am J Med. 1968;45:756–79.PubMedCrossRefGoogle Scholar
  21. 21.
    Pak CY, Moe OW, Sakhaee K, Peterson RD, Poindexter JR. Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol. 2005;173:1606–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kok DJ, Papapoulos SE, Bijvoet OL. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet. 1986;1:1056–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Sakhaee K, Nigam S, Snell P, Hsu MC, Pak CY. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab. 1987;65:974–79.PubMedCrossRefGoogle Scholar
  24. 24.
    Deren JJ, Porush JG, Levitt MF, Khilnani MT. Nephrolithiasis as a complication of ulcerative colitis and regional enteritis. Ann Intern Med. 1962;56:843–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Moe OW, Abate N, Sakhaee K. Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31:895–914.PubMedCrossRefGoogle Scholar
  26. 26.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Wakita N, Adachi M, et al. Two male siblings with hereditary renal hypouricemia and exercise-induced ARF. Am J Kidney Dis. 2003;42:1287–92.PubMedCrossRefGoogle Scholar
  27. 27.
    Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol. 2004;15:164–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65:1422–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5:1277–81.PubMedCrossRefGoogle Scholar
  30. 30.
    Cameron M, Maalouf NM, Poindexter J, Adams-Huet B, Sakhaee K, Moe OW. The diurnal variation in urine acidification differs between normal individuals and uric acid stone formers. Kidney Int. 2012;81:1123–30.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001;60:757–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Pak CY, Waters O, Arnold L, Holt K, Cox C, Barilla D. Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest. 1977;59:426–31.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Pak C, Holt K, Britton F, Peterson R, Crother C, Ward D. Assesment of pathogenetic role of uric acid, monpotassium urate, monoammonium urate, monosodium urate in hyperuricosuric calcium oxalate nephrolithiasis Miner Electrolyte Metab. 1980;4:130–6.Google Scholar
  34. 34.
    Pak CY, Arnold LH. Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med. 1975;149:930–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Lonsdale K. Epitaxy as a growth factor in urinary calculi and gallstones. Nature. 1968;217:56–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Zerwekh JE, Holt K, Pak CY. Natural urinary macromolecular inhibitors: attenuation of inhibitory activity by urate salts. Kidney Int. 1983;23:838–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Grover PK, Ryall RL. Urate and calcium oxalate stones: from repute to rhetoric to reality. Miner Electrolyte Metab. 1994;20:361–70.PubMedGoogle Scholar
  38. 38.
    Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986;30:422–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens. 2004;13:181–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Cameron MA, Baker LA, Maalouf NM, Moe OW, Sakhaee K. Circadian variation in urine pH and uric acid nephrolithiasis risk. Nephrol Dial Transplant. 2007;22:2375–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Freed SZ. The alternating use of an alkalizing salt and acetazolamide in the management of cystine and uric acid stones. J Urol. 1975;113:96–9.PubMedGoogle Scholar
  42. 42.
    Gordon EE, Sheps SG. Effect of acetazolamide on citrate excretion and formation of renal calculi. N Engl J Med. 1957;256:1215–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE. Topiramate-induced nephrolithiasis. J Endourol. 2002;16:229–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Gelzayd EA, Breuer RI, Kirsner JB. Nephrolithiasis in inflammatory bowel disease. Am J Dig Dis. 1968;13:1027–34.PubMedCrossRefGoogle Scholar
  45. 45.
    Knudsen L, Marcussen H, Fleckenstein P, Pedersen EB, Jarnum S. Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13:433–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Bambach CP, Robertson WG, Peacock M, Hill GL. Effect of intestinal surgery on the risk of urinary stone formation. Gut. 1981;22:257–63.PubMedCrossRefGoogle Scholar
  47. 47.
    Fukushima T, Yamazaki Y, Sugita A, Tsuchiya S. Prophylaxis of uric acid stone in patients with inflammatory bowel disease following extensive colonic resection. Gastroenterol Jpn. 1991;26:430–4.PubMedGoogle Scholar
  48. 48.
    Clarke AM, McKenzie RG. Ileostomy and the risk of urinary uric acid stones. Lancet. 1969;2:395–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Obialo CI, Clayman RV, Matts JP, Fitch LL, Buchwald H, Gillis M, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int. 1991;39:1249–54.PubMedCrossRefGoogle Scholar
  50. 50.
    Yu T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967;67:1133–48.PubMedCrossRefGoogle Scholar
  51. 51.
    Wyngaarden JB, Kelley WN. Gout. In: Stanbury JB, Wyngaarden JB, Frederickson DS, editors. The metabolic basis of inherited disease. 3rd ed. New York: McGraw-Hill; 1972.p. 889–968.Google Scholar
  52. 52.
    Roche A, Perez-Duenas B, Camacho JA, Torres RJ, Puig JG, García-Cazorla A, et al. Efficacy of rasburicase in hyperuricemia secondary to Lesch-Nyhan syndrome. Am J Kidney Dis. 2009;53:677–80.PubMedCrossRefGoogle Scholar
  53. 53.
    Bollee G, Harambat J, Bensman A, Knebelmann B, Daudon M, Ceballos-Picot I. Adenine phosphoribosyltransferase deficiency. Clin J Am Soc Nephrol. 2012;7:1521–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Yu T, Weinreb N, Wittman R, Wasserman LR. Secondary gout associated with chronic myeloproliferative disorders. Semin Arthritis Rheum. 1976;5:247–56.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Charles and Jane Pak Center for Mineral Metabolism and Clinical ResearchUniversity of Texas Soutwestern Medical CenterDallasUSA

Personalised recommendations